Nested Case–Control Study of Autoimmune Disease in an Asbestos-Exposed Population

Curtis W. Noonan, Jean C. Pfau, Theodore C. Larson, and Michael R. Spence

OBJECTIVE: To explore the potential association between asbestos exposure and risk of autoimmune disease, we conducted a case–control study among a cohort of 7,307 current and former residents of Libby, Montana, a community with historical occupational and environmental exposure to asbestos-contaminated vermiculite.

METHODS: Cases were defined as those who reported having one of three systemic autoimmune diseases (SAIDs): systemic lupus erythematosus, scleroderma, or rheumatoid arthritis (RA). Controls were randomly selected at a 3:1 ratio from among the remaining 6,813 screening participants using frequency-matched age and sex groupings.

RESULTS: The odds ratios (ORs) and 95% confidence intervals (CIs) for SAIDs among those ≥65 years of age who had worked for the vermiculite mining company were 2.14 (95% CI, 0.90–5.10) for all SAIDs and 3.23 (95% CI, 1.31–7.96) for RA. In this age group, exposure to asbestos while in the military was also an independent risk factor, resulting in a tripling in risk.

CONCLUSION: These preliminary findings support the hypothesis that asbestos exposure is associated with autoimmune disease. Refined measurements of asbestos exposure and SAID status among this cohort will help to further clarify the relationship between these variables.

KEY WORDS: asbestos, autoimmune, Libby, lupus, rheumatoid arthritis, scleroderma, vermiculite.

An association between occupational exposures of inhaled particulates and autoimmunity was postulated as early as 1914, when Bramwell reported increased frequency of diffuse scleroderma (SSc) in stone masons. Although genetic factors undoubtedly exist that affect the development of systemic autoimmune diseases (SAIDs) in certain individuals, the concordance of SAIDs among identical twins is only 25–40%, suggesting that environmental factors play a substantial role (Powell et al. 1999).

Indeed, several environmental agents are implicated in triggering or accelerating SAIDs, including mercury, iodine, vinyl chloride, certain pharmaceuticals, and crystalline silica. However, much more research is needed to determine the mechanisms and epidemiology linking exposures to development of SAIDs. There is considerable epidemiologic evidence supporting the hypothesis that occupational silica exposure is associated with a variety of SAIDs, including SSc, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), glomerulonephritis, and small vessel vasculitis (Koeger et al. 1995; Parks et al. 1999, 2002; Powell et al. 1999; Steenland and Goldsmith 1995). Research regarding asbestos exposure and SAIDs has been much more limited.

Asbestos-related lung disease continues to be a serious and significant problem worldwide despite increasing awareness of health hazards of asbestos inhalation. Asbestos exposure is associated with various lung conditions, including fibrosis, pleural plaques, and cancer. Although the exact mechanisms leading to the progression of these conditions have not been fully explained, there is evidence that some of the lung abnormalities seen with both asbestos and silica exposures are immunologically mediated (Hamilton et al. 1996; Holian et al. 1993; Perkins et al. 1993). Nevertheless, it is unclear how these innate immune responses might translate to specific humoral responses. Increased serum immunoglobulins (Ig), positive autotaxin antibody (ANA) tests, and immune complexes have been reported in small cohorts of individuals exposed to asbestos (Lange 1980; Nigam et al. 1993; Pfau et al. 2005; Zerva et al. 1989), but no comprehensive study has been undertaken to assess the association between asbestos exposure and autoimmune disease.

Our major objective, therefore, is to establish whether such an association exists, and the community of Libby, Montana, provides a unique opportunity to investigate this question. Individuals in this population experienced significant exposures that occurred as a result of asbestos-contaminated vermiculite mining near the community. From the early 1920s to 1990, the world’s largest vermiculite deposits, located near Libby, were mined and processed. Vermiculite is a silicate mineral with unique properties and numerous commercial applications (Lockey 1984). The fibrous minerals contaminating Libby vermiculite have been characterized as both regulated asbestos fibers (e.g., tremolite and other amphibole forms) and unregulated fibers (e.g., winchite and richterite) (Meeker et al. 2003). The various mining, transportation, and processing activities as well as the personal and commercial use of vermiculite in the community have led to widespread environmental exposures in the Libby area with this asbestos-contaminated vermiculite. Potential asbestos exposures in this community have been documented not only in the miners but also in their family members as well as anyone who used the vermiculite or played near the mine tailings (Dixon et al. 1985). A mortality study in this community found more than 40-fold increases in standardized mortality ratios for asbestosis, and elevated mortality also was observed for malignant neoplasm of respiratory and intrathoracic organs (Horton et al., in press).

Recently, the Agency for Toxic Substances and Disease Registry (ATSDR) conducted an extensive screening program of >7,300 individuals from this community (Peipins et al. 2003). The initial results of this screening program identified various routes of exposure in the community and how those routes of exposure were associated with abnormalities on chest radiographs (Peipins et al. 2003). In addition, when the ATSDR performed its screening in Libby during 2000–2001, 494 (6.7%) participants indicated that they had been diagnosed with SLE, SSc, or RA (Noonan et al. 2005). By comparison, a prevalence of <1% for these three conditions...
combined would be expected based on pooled estimates from 43 prevalence studies (Jacobson et al. 1997). In the present study, we take these data a step further by exploring the association of these systemic autoimmune conditions with various parameters of asbestos and/or vermiculite exposure using a nested case-control approach.

Materials and Methods
All human subjects provided informed consent for this study under a protocol approved by the institutional review board for the Centers for Disease Control and Prevention. The details of the ATSDR screening program are described elsewhere (Peipins et al. 2003). Briefly, individuals were eligible for the screening program if they had resided, worked, attended school, or participated in other activities in the Libby area for at least 6 months before 31 December 1990. All screening participants who were ≥ 18 years of age and not pregnant (n = 6,668) were offered chest radiographs. Two independent B readers evaluated the radiographs for each subject for pleural and parenchymal abnormalities. If these two readers disagreed regarding the presence of asbestos-related abnormalities, a third reader was called to adjudicate the difference. Participants were classified as “positive” for pleural or parenchymal abnormalities if at least two of three B readers observed this type of abnormality on chest radiographs. Participants also received spirometry testing and were considered to have abnormal findings if they had a forced vital capacity (FVC) < 80% predicted and a ratio of 1 sec forced expiratory volume (FEV1) to FVC that is ≥ 70% predicted. Data on exposure to asbestos-contaminated vermiculite were based on occupational, residential, and recreational histories collected during in-person interviews. Demographic variables and data on other potential covariates were also collected by in-person interview.

This study was conducted in two phases. The initial characterization of cases (n = 494) with SAIDs were those participants who, during the 2000–2001 ATSDR screening program, responded affirmatively to the question "Have you ever had rheumatoid arthritis, systemic lupus erythematosus, or lupus?" Potential controls were those screening participants who answered negatively to this question. Controls were randomly selected from within strata of sex and 10-year age groups at a 3:1 control-to-case ratio (n = 1,482) (Figure 1).

The initial screening question on SAIDs was collected only to identify screening participants with health conditions that could have an impact on pulmonary function or fibrosis. The second phase of this study involved a mailed questionnaire to confirm the original self-reports of SAIDs and to identify which of the three conditions the potential cases were reporting. The follow-up survey was mailed to all 494 potential SAID cases for whom current addresses were available. The follow-up survey queried potential cases on whether or not they still considered themselves to have one of the three indicated SAIDs, which SAID(s) they had, whether or not their SAIDs were diagnosed by a physician, and whether or not they were taking medication or other treatment for their condition. For those reporting RA, additional questions were asked to confirm the type of arthritis on which they were reporting (i.e., RA, osteoarthritis, or general arthritis). This follow-up survey was approved by the University of Montana investigational review board.

Analyses were conducted using unconditional logistic regression using SAS (version 9; SAS Institute Inc., Cary, NC). The presence or absence of SAIDs or a specific autoimmune disease in the postmailing analysis was used as the dependent variable. The various pathways of exposure to vermiculite and/or asbestos were considered as the main independent variables of interest. Test for trend with increasing numbers of exposure pathways was assessed using the Cochran-Armitage test. Potential founders included indications of restrictive spirometry and the presence of pleural or parenchymal abnormalities. These pulmonary features were the main outcomes of the ATSDR screening program and could be independently associated with both asbestos exposure and biomarkers of autoimmunity (Pfau et al. 2005). For the final unconditional logistic regression models, all vermiculite/asbestos exposure pathways and other potential risk factors were considered. Criteria for inclusion in the final model included statistical significance of the explanatory variable (p < 0.10), the presence of a confounding effect on other variables, and the fit of the model.

Results
The distribution of SAID subjects for selected characteristics are presented in Table 1. Among the 494 subjects responding positively to the original SAID screening question, 287 (58%) were women. More than 75% of SAID subjects lived in Libby for at least 15 years. Follow-up mailed questionnaires were sent to all 494 subjects who were classified as having SAIDs in the initial analysis. Of these, 208 (42%) participants responded. Among those responding, 161 participants confirmed that they had a physician-diagnosed SAID. The proportional distribution of those reporting physician-diagnosed SAIDs was similar to the original 494 who reported SAIDs with regard to sex, age, smoking history, and years lived in Libby (Table 1). Among those

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Case and control selection from initial screening population. DPHHS, Montana Department of Public Health and Human Services. Lupus refers to SLE.
reporting physician-diagnosed SAIDs, 129 participants indicated that they had physician-diagnosed RA, 70% of whom took medication for RA. Thirty participants indicated that they had physician-diagnosed SLE, 63% of whom took medication for SLE. Another four participants indicated that they had SSc, and two of those took medication for SSc.

Considering the initial case group (n = 494), the distribution of years of residence was not different for cases and controls (χ² = 0.57, p < 0.90). Current and former smokers were more common among SAID subjects [odds ratio (OR) = 1.72; 95% confidence interval (CI), 1.22–2.44]. SAIDs also were associated with parenchymal abnormalities and with restrictive spirometry but not strongly with pleural abnormalities (Table 2). These associations remained consistent when evaluating those reporting physician-diagnosed SAIDs (n = 161) (Table 2). Both restrictive spirometry and parenchymal abnormalities as well as current or former smoking were included in the unconditional logistic regression models for vermiculite/asbestos exposure and risk of SAIDs.

The adjusted ORs for various potential exposure pathways to vermiculite and asbestos and risk of SAIDs are presented in Table 3. Previous occupation with the mining company yielded no overall increased risk for SAIDs (OR = 1.03; 95% CI, 0.69–1.58). However, we observed elevated ORs for previous occupation with the mining company among those ≥ 65 years of age at the time of the screening, particularly for RA. Among other occupational vermiculite exposures, “dust or vermiculite exposure at jobs other than W.R. Grace/Zonolite” was the most consistently associated with reporting of any SAID or RA specifically. Among other occupations with potential exposure to asbestos, only those reporting asbestos exposure in the military were at increased risk for SAIDs and RA, yielding ORs of 1.70 and 2.11, respectively. Several reported activities or experiences were associated with increased risk of any SAID or RA specifically. Considering all exposure pathways collectively, increasing opportunities for vermiculite and/or asbestos exposure yielded increased risk estimates for both SAIDs and RA. For this age group, working at W.R. Grace/Zonolite also resulted in a 3-fold greater risk for RA. Elevated ORs were also observed for several nonoccupational exposures to vermiculite (Table 5).

**Discussion**

Although there is considerable epidemiologic evidence supporting the hypothesis that occupational silica exposure is associated with a variety of SAIDs, research regarding asbestos

---

**Table 1. Distribution (n [%]) of selected characteristics for participants reporting any SAID, RA, or SLE.**

| Characteristic          | SAIDs a (n = 494) | SAIDs b (n = 161) | RA (n = 129) | SLE (n = 30) |
|-------------------------|-------------------|-------------------|--------------|--------------|
| Sex                     |                   |                   |              |              |
| Male                    | 207 (41.9)        | 69 (42.9)         | 61 (47.3)    | 2 (6.7)      |
| Female                  | 287 (58.1)        | 92 (57.1)         | 68 (52.7)    | 28 (93.3)    |
| Age (years) b           |                   |                   |              |              |
| 17–44                   | 69 (14.0)         | 18 (11.2)         | 15 (11.6)    | 5 (16.7)     |
| 45–64                   | 258 (52.2)        | 97 (60.3)         | 80 (62.0)    | 21 (70.0)    |
| ≥ 65                    | 167 (33.8)        | 46 (28.6)         | 34 (26.4)    | 4 (13.3)     |
| Smoking history         |                   |                   |              |              |
| Never                   | 163 (33.1)        | 51 (31.9)         | 35 (27.3)    | 11 (36.7)    |
| Ex-smoker               | 214 (43.4)        | 78 (48.8)         | 64 (50.0)    | 14 (46.7)    |
| Current                 | 116 (23.5)        | 31 (19.4)         | 29 (22.7)    | 5 (16.7)     |
| Years lived in Libby c  |                   |                   |              |              |
| 0.5–14                  | 118 (23.9)        | 37 (22.9)         | 28 (21.7)    | 0 (0.0)      |
| 15–27                   | 133 (26.9)        | 41 (25.5)         | 36 (27.9)    | 9 (30.0)     |
| 28–39                   | 120 (24.3)        | 47 (29.2)         | 39 (30.2)    | 12 (40.0)    |
| ≥ 40                    | 123 (24.9)        | 36 (22.4)         | 26 (20.2)    | 9 (30.0)     |

*Subjects responding positively to original screening question on SAIDs. +Subjects confirming physician-diagnosed SAIDs in follow-up mailing. #Age as of 1 January 2000.

**Table 2. Association between SAIDs and positive findings for chest radiograph and pulmonary function.**

| Characteristic          | SAIDs a (n = 494) | SAIDs b (n = 161) | RA (n = 129) | SLE (n = 30) |
|-------------------------|-------------------|-------------------|--------------|--------------|
| Pulmonary function test abnormality c | 90 | 1.76 (1.34–2.32) | 37 | 2.23 (1.50–3.33) |
| Pleural abnormality c  | 134 | 1.15 (0.91–1.45) | 46 | 1.25 (0.87–1.79) |
| Parenchymal abnormality c | 27 | 2.54 (1.51–4.27) | 9 | 2.62 (1.23–5.58) |

*Subjects responding positively to original screening question on SAIDs. †Subjects confirming physician-diagnosed SAIDs in follow-up mailing. ‡FVC < 80% predicted and an FEV1:FVC ratio 70% predicted. ¤At least two of three B readers observed this type of abnormality on chest radiographs.

**Table 3. Adjusted ORs (95% CIs) for vermiculite/asbestos exposure and risk of any SAID or RA specifically, Libby, Montana.**

| Exposure pathway            | SAIDs a (n = 494) | SAIDs b (n = 161) | RA (n = 129) |
|-----------------------------|-------------------|-------------------|--------------|
| Ever work for W.R. Grace/Zonolite |                   |                   |              |
| Age ≤ 65 years              | 0.57 (0.29–1.11) | 0.74 (0.29–1.91) | 0.52 (0.16–1.70) |
| Age > 65 years              | 1.47 (0.82–2.63) | 2.14 (0.90–5.10) | 3.23 (1.31–7.96) |
| Contract worker for W.R. Grace/Zonolite | 1.29 (0.89–1.88) | 1.21 (0.67–2.20) | 1.29 (0.89–1.89) |
| Live with W.R. Grace/Zonolite workers | 1.19 (0.93–1.53) | 1.29 (0.88–1.90) | 1.23 (0.80–1.90) |
| Dust or vermiculite exposure at other jobs | 1.33 (1.08–1.64) | 1.54 (1.10–2.15) | 1.65 (1.14–2.39) |

*Subjects responding positively to original screening question on SAIDs. †Subjects confirming physician-diagnosed SAIDs in follow-up mailing. ‡FVC < 80% predicted and an FEV1:FVC ratio 70% predicted. ▲At least two of three B readers observed this type of abnormality on chest radiographs.
exposure and SAIDs has been much more limited. The preliminary findings presented here support the hypothesis that asbestos exposure is associated with the presence of autoimmune disease. We found increased risk for SAIDs among those reporting occupational and environmental or recreational exposures to vermiculite and/or asbestos. Increased risk estimates were found for increasing numbers of reported exposure pathways. The risk estimates by exposure pathway remained elevated and in some cases increased after restricting the cases to those who responded to a follow-up survey and confirmed that they had a physician-diagnosed SAID or RA specifically. We recognize the limitation of this approach of combining exposure pathways of unequal intensity and duration, but it also provides an analysis that parallels the previously observed findings of asbestos exposure and lung abnormalities in this population (Peipins et al. 2003).

The multivariable analysis identified specific exposure pathways that were independently associated with risk of SAIDs, including older subjects who had worked for the mining company. Among older participants, we also observed increased risk estimates for SAIDs and RA among those reporting exposure to asbestos in the military. The risk for military asbestos exposure was independent of the elevated risk for previous work at W.R. Grace/Zonolite and other Libby exposure pathways. These findings suggested that asbestos exposure in general rather than Libby vermiculite exposure in particular could be relevant to SAID etiology.

These findings were consistent with a recent immunologic study we undertook among a small group of volunteers from this same Libby community (Pflau et al. 2005). The results of that study supported the hypothesis that increased frequency of positive ANA would be found in the Libby group compared to an age- and sex-matched unexposed population in Missoula, Montana. Among the Libby volunteers, the titers of the positive ANAs were positively correlated with the strength of the individual’s estimated asbestos exposure. Previous studies have measured several immune parameters in populations exposed to asbestos. Investigators in India demonstrated increased IgG, IgA, and positive ANAs in asbestos-exposed individuals, compared to controls, even in the absence of apparent lung disease (Nigam et al. 1993). This finding suggested that immune alterations may precede the onset of asbestos-related disease. A high frequency of positive ANAs was also found in a Japanese group of asbestos plant workers (Tamura et al. 1993). Interestingly, a 3-year follow-up study of the Japanese group showed significant correlation of positive ANAs with progression of disease, leading to additional diagnoses of asbestos-related diseases in a previously healthy group (Tamura et al. 1996). A study of Greek residents exposed to asbestos-contaminated whitewash showed a correlation of immune abnormalities particularly in individuals with pleural plaques (Zerva et al. 1989), whereas the Japanese study showed a greater effect in individuals with diffuse fibrosis but not pleural plaques. In addition, a Polish study reported increased ANA frequency particularly in individuals exhibiting lung function deficits (Lange 1980).

Despite some inconsistency between the studies cited above, all of these immunologic studies illustrate two important considerations. First, asbestos exposure is clearly associated with indices of autoimmune responses. Second, although the details vary, the autoimmune responses appear to correlate with asbestos-related disease, suggesting a possible role for the autoimmune responses in the disease process. The temporal relationship among asbestos exposure, autoimmune response, and asbestos-related diseases is uncertain and beyond the scope of the present study. Nevertheless, our findings of strong associations between asbestos and/or vermiculite exposure and risk of SAIDs remained robust after adjusting for objectively characterized pulmonary conditions that could be associated with asbestos exposure.

As described previously, the initial case group was based on those who responded positively to a screening question about autoimmune conditions. Asbestos exposure and SAIDs is a relatively novel avenue of research, so it is not expected that participants would overreport SAIDs because of a suspected association. For the same reason, we would not expect self-reported asbestos exposure to be differentially misclassified with respect to SAID status. As a first step toward improving disease characterization, we conducted a mailing to all participants who indicated having an SAID during the initial screening program. Of those who responded to the mailing, almost 23% were unable to confirm that they had RA, SLE, or SSc. In general, when restricting the analyses to those reporting any physician-diagnosed SAID or RA specifically, the risk estimates for several pathways of asbestos and/or vermiculite exposure were increased. Comparisons of risk estimates between the original group of suspected cases and those who reconfirmed diagnosis should be made with caution, however, because both sets of cases are based on self-report.

Given the unique circumstances of community asbestos exposure and the resulting screening program, it is also possible that there was a case ascertainment error that was biased with respect to exposure. Specifically, those with greater history of asbestos exposure would be more likely to have lung abnormalities or frank asbestos-related disease and would have received more intensive medical care. Better medical care could, in turn, result in a higher likelihood of being diagnosed with
other conditions such as SAIDs. This concern is somewhat tempered by the fact that pleural abnormality, the asbestos-related condition that has been most strongly associated with asbestos exposure in this population, was not associated with reporting of SAIDs.

It is also possible, but less likely, that disease status was misclassified among controls. Controls were chosen from among those in the cohort who responded negatively to the screening questions about autoimmune conditions, but we did not confirm the absence of disease among these selected controls. It is possible that some participants with SAIDs did not understand the screening questions and were inappropriately included in the pool of potential controls. This possibility is expected to be of minor concern based on the low prevalence of these conditions in the general population (Jacobson et al. 1997).

This study could suffer from exposure misclassification because these measures were based on self-reported responses as part of a large community-based screening program. Recall bias is a possibility, and persons with chronic health conditions such as SAIDs could overreport past exposure to vermiculite. In the future, we plan to improve on exposure characterization for this cohort, incorporating job exposure matrices and quantitative or semiquantitative assessment of other exposure pathways.

In summary, these preliminary findings provide a unique insight into the risk for autoimmune disease among a population with historical asbestos exposures. These results warrant a more comprehensive case–control study of this population with improved disease and exposure characterization and the incorporation of biomarkers of genetic susceptibility.

REFERENCES

Bramwell B. 1914. Diffuse scleroderma: its frequency; its occurrence in stone masons: its treatment by fibrilysis. Edinburgh Med J 12:287.

Dixon G, Doris J, Freed J, Wood P, May I, Chambers T. 1985. Exposure Assessment for Asbestos-Contaminated Vermiculite. EPA-560/5-85-013. Washington, DC: U.S. Environmental Protection Agency, Office of Pesticides and Toxic Substances.

Hamilton RF, Iyer LL, Hollan A. 1996. Asbestos induces apoptosis in human alveolar macrophages. Am J Physiol 271:L813–L819.

Hollan A, Uthman MO,戈尔ova T, Brawn SD, Hamilton RF Jr. 1997. Asbestos and silica-induced changes in human alveolar macrophage phenotype. Environ Health Perspect 105(suppl 5):1139–1142.

Horton K, Kapil V, Larsen T, Muravov O, Melnikova N. In press. A review of the federal government’s health activities in response to asbestos-contaminated ore found in Libby, Montana. Inhal Toxicol.

Jacobson DL, Gange SJ, Rose NR, Graham NM. 1997. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84:223–249.

Koeper AC, Lang T, Alcaix D, Milleron B, Rozenberg S, Chabri P, et al. 1995. Silica-associated connective tissue disease. A study of 24 cases. Medicine (Baltimore) 74:203–218.

Lange A. 1980. An epidemiological survey of immunological abnormalities in asbestos workers. II. Serum immunoglobulin levels. Environ Res 23:176–183.

Lockey JE. 1984. Nonasbestos fibrous minerals. Clin Chest Med 2:203–218.

Meeker G, Bern A, Brownfield I, Lowers H, Sutley S, Hoefen T, et al. 2003. The composition and morphology of amphiboles from the Rainy Creek Complex, near Libby, Montana. Am Mineral 88:1955–1969.

Nigam SK, Suthar AM, Patel MM, Karnik AB, Dave SK, Kashyap SK, et al. 1993. Humoral immunological profile of workers exposed to asbestos in asbestos mines. Indian J Med Res 98:274–277.

Nooman C, Plou J, Spence M, Larson T. 2005. Asbestos exposure and risk of autoimmune disease [Abstract]. Am J Epidemiol 161(11 Suppl):S124.

Parks CG, Conrad K, Cooper GS. 1999. Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 107(suppl 5):793–802.

Parks CG, Cooper GS, Nylander-French LA, Sanderson WT, Dement JM, Cohen PL, et al. 2002. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum 48:1840–1850.

Peipins LA, Lewin M, Campolucci S, Lybarger JA, Miller A, Middleton D, et al. 2003. Radiographic abnormalities and exposure to asbestos-contaminated vermiculite in the community of Libby, Montana, USA. Environ Health Perspect 111:1753–1759.

Perkins RC, Scheule RK, Hamilton R, Gomes G, Feidman G, Hollan A. 1993. Human alveolar macrophage cytokine release in response to in vitro and in vivo asbestos exposure. Exp Lung Res 19:95–105.

Plou JC, Sentissi JJ, Weiler G, Putnam EA. 2005. Assessment of autoimmune responses associated with asbestos exposure in Libby, Montana, USA. Environ Health Perspect 113:25–30.

Powell JJ, Van de Water J, Gershwin ME. 1999. Evidence for the role of environmental agents in the initiation or progression of autoimmune conditions. Environ Health Perspect 107(suppl 5):675–677.

Steenland K, Goldsmith DF. 1995. Silica exposure and autoimmune diseases. Am J Ind Med 28:603–608.

Tamura M, Tokuyama T, Yonedo T, Kasuga H, Narita M, et al. 1993. Study on the relationship between appearance of autoantibodies and chest X-ray findings of asbestos plant employees [in Japanese]. Sangyo Igaku 35:406–412.

Tamura M, Tokuyama T, Kasuga H, Yonedo T, Miyazaki R, Narita N. 1996. Study on the relationship between appearance of autoantibodies and chest X-ray findings in asbestos plant employees in Japan [in Japanese]. Sangyo Eiseigaku Zasshi 38:139–141.

Zerva LV, Constantopoulos SH, Moutsopoulos HM. 1989. Humoral immunity alterations after environmental asbestos exposure. Respir Med 83:237–241.